Investor Relations

iCo Investor Relations

Please visit the TSX site for up to date trading information.

Fact Sheets

Corporate fact sheet ICO_fact_sheet.pdf
iCo-007 iCo-007_fact_sheet.pdf
iCo-008 iCo-008_fact_sheet.pdf
iCo-009 iCo-009_fact_sheet.pdf

Press Releases

For iCo Press Releases, please visit here.

Media Coverage

For recent iCo Media Coverage, please visit here.

Upcoming Events

For upcoming events, please visit here.

Frequently Asked Questions

What is iCo Therapeutics’ Business?

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications.

What are iCo’s Products?

iCo has exclusive worldwide rights to two products, iCo-007, in Phase I for the treatment of Diabetic Macular Edema, and iCo-008, a product with Phase II clinical history to be developed for severe ocular allergies. iCo Therapeutics has an exclusive option to license iCo-009, a oral reformulation of Amphotericin B for sight and life threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other IV administered drugs to the oral route of administration.

What exchange is iCo traded on, and what is the symbol?

iCo is traded on the Toronto Stock Exchange (Venture) under the symbol “ICO”.

Where can I access iCo’s financial statements?

Please visit SEDAR.

When was iCo Therapeutics founded?

iCo Therapeutics was founded in 2005 by Andrew Rae, John Clement and John Meekison.

When is iCo’s fiscal year-end date?

iCo Therapeutics operates on a fiscal year ending December 31.

Who is iCo’s Transfer Agent?

Communication concerning transfer requirements, lost certificates, change of address and other similar inquiries should be addressed to our transfer agent:

Computershare Investor Services Inc.
In person delivery:
510 Burrard Street,
Suite 300
Vancouver, BC

Toll-free 1-800-564-6253
Fax: 1-888-453-0330

How can I get more information on iCo Therapeutics?

Press releases, stock information, notice of upcoming events and corporate fact sheets are available on iCo’s website. If you would like to receive a full investor package or a copy of the corporate presentation, please contact Frederica Bell, Director of Corporate Development at 604-602-9414 × 228 or .

Forward Looking Statements

Certain statements included in this website may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics’ current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this website. Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.